Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients

Essam R. Othman, Daniela Hornung, Mostafa Hussein, Ibraheem I. Abdelaal, Ayat A. Sayed, Ahmed N. Fetih, Ayman Al-Hendy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction We examine serum levels sTNFR-I and sTNFR-II in endometriosis patients, and their role as biomarkers of endometriosis. Material and methods Women were diagnosed with endometriosis during laparoscopy to investigate pelvic pain and/or infertility (N = 62). Control group included women with pelvic pain and/or infertility, whose laparoscopy showed no abnormalities (N = 55). Serum concentrations of sTNFR-I and sTNFR-II were measured using Bioplex Protein Array system. Non-parametric statistics were used. Results Endometriosis patients had significantly higher levels of sTNFR-I than controls (257.46 pg/ml, IQR = 2.37-1048.92 versus 130.39 pg/ml, IQR = 0.99-361.1 respectively, P value = 0.01). For TNFR-II, difference between women with (232 pg/ml, IQR = 0.0-624.4), and women without (132.93 pg/ml, IQR = 0.0-312.81) endometriosis was not significant (P value = 0.05). Early stage endometriosis patients had significantly higher level of sTNFR-I (559.13, IQR = 1.82-1289.86) and sTNFR-II (248.8, IQR = 0-644.65) than control women (P value is 0.01 for TNFR-I and 0.04 for TNFR-II). Levels of sTNFR-I and sTNFR-II were comparable for advanced endometriosis and controls, and between early and advanced endometriosis. As a biomarker for all- stage endometriosis, sTNFR-I produces AUC of 0.62, sensitivity of 61%, and specificity of 47.3%, at a cutoff of 81.87 pg/ml. For early stage disease, sTNFR-I yields AUC of 0.68, sensitivity of 60.7%, specificity of 75%, at a cutoff of 351.22 pg/ml. Conclusion sTNFR-I is significantly higher in serum of endometriosis patients than controls. As an endometriosis biomarker, sTNFR-I achieves better performance for early stage disease.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume200
DOIs
StatePublished - May 1 2016

Fingerprint

Tumor Necrosis Factor Receptors
Endometriosis
Tumor Necrosis Factor-alpha
Serum
Pelvic Pain
Biomarkers
Laparoscopy
Infertility
Area Under Curve
Receptors, Tumor Necrosis Factor, Type I
Sensitivity and Specificity
Protein Array Analysis
Nonparametric Statistics

Keywords

  • Endometriosis
  • Non invasive diagnosis
  • Serum
  • Soluble TNF receptors

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients. / Othman, Essam R.; Hornung, Daniela; Hussein, Mostafa; Abdelaal, Ibraheem I.; Sayed, Ayat A.; Fetih, Ahmed N.; Al-Hendy, Ayman.

In: European Journal of Obstetrics Gynecology and Reproductive Biology, Vol. 200, 01.05.2016, p. 1-5.

Research output: Contribution to journalArticle

Othman, Essam R. ; Hornung, Daniela ; Hussein, Mostafa ; Abdelaal, Ibraheem I. ; Sayed, Ayat A. ; Fetih, Ahmed N. ; Al-Hendy, Ayman. / Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients. In: European Journal of Obstetrics Gynecology and Reproductive Biology. 2016 ; Vol. 200. pp. 1-5.
@article{e95ecad37eb3404eb6f27351c602dfa6,
title = "Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients",
abstract = "Introduction We examine serum levels sTNFR-I and sTNFR-II in endometriosis patients, and their role as biomarkers of endometriosis. Material and methods Women were diagnosed with endometriosis during laparoscopy to investigate pelvic pain and/or infertility (N = 62). Control group included women with pelvic pain and/or infertility, whose laparoscopy showed no abnormalities (N = 55). Serum concentrations of sTNFR-I and sTNFR-II were measured using Bioplex Protein Array system. Non-parametric statistics were used. Results Endometriosis patients had significantly higher levels of sTNFR-I than controls (257.46 pg/ml, IQR = 2.37-1048.92 versus 130.39 pg/ml, IQR = 0.99-361.1 respectively, P value = 0.01). For TNFR-II, difference between women with (232 pg/ml, IQR = 0.0-624.4), and women without (132.93 pg/ml, IQR = 0.0-312.81) endometriosis was not significant (P value = 0.05). Early stage endometriosis patients had significantly higher level of sTNFR-I (559.13, IQR = 1.82-1289.86) and sTNFR-II (248.8, IQR = 0-644.65) than control women (P value is 0.01 for TNFR-I and 0.04 for TNFR-II). Levels of sTNFR-I and sTNFR-II were comparable for advanced endometriosis and controls, and between early and advanced endometriosis. As a biomarker for all- stage endometriosis, sTNFR-I produces AUC of 0.62, sensitivity of 61{\%}, and specificity of 47.3{\%}, at a cutoff of 81.87 pg/ml. For early stage disease, sTNFR-I yields AUC of 0.68, sensitivity of 60.7{\%}, specificity of 75{\%}, at a cutoff of 351.22 pg/ml. Conclusion sTNFR-I is significantly higher in serum of endometriosis patients than controls. As an endometriosis biomarker, sTNFR-I achieves better performance for early stage disease.",
keywords = "Endometriosis, Non invasive diagnosis, Serum, Soluble TNF receptors",
author = "Othman, {Essam R.} and Daniela Hornung and Mostafa Hussein and Abdelaal, {Ibraheem I.} and Sayed, {Ayat A.} and Fetih, {Ahmed N.} and Ayman Al-Hendy",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.ejogrb.2016.02.025",
language = "English (US)",
volume = "200",
pages = "1--5",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients

AU - Othman, Essam R.

AU - Hornung, Daniela

AU - Hussein, Mostafa

AU - Abdelaal, Ibraheem I.

AU - Sayed, Ayat A.

AU - Fetih, Ahmed N.

AU - Al-Hendy, Ayman

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Introduction We examine serum levels sTNFR-I and sTNFR-II in endometriosis patients, and their role as biomarkers of endometriosis. Material and methods Women were diagnosed with endometriosis during laparoscopy to investigate pelvic pain and/or infertility (N = 62). Control group included women with pelvic pain and/or infertility, whose laparoscopy showed no abnormalities (N = 55). Serum concentrations of sTNFR-I and sTNFR-II were measured using Bioplex Protein Array system. Non-parametric statistics were used. Results Endometriosis patients had significantly higher levels of sTNFR-I than controls (257.46 pg/ml, IQR = 2.37-1048.92 versus 130.39 pg/ml, IQR = 0.99-361.1 respectively, P value = 0.01). For TNFR-II, difference between women with (232 pg/ml, IQR = 0.0-624.4), and women without (132.93 pg/ml, IQR = 0.0-312.81) endometriosis was not significant (P value = 0.05). Early stage endometriosis patients had significantly higher level of sTNFR-I (559.13, IQR = 1.82-1289.86) and sTNFR-II (248.8, IQR = 0-644.65) than control women (P value is 0.01 for TNFR-I and 0.04 for TNFR-II). Levels of sTNFR-I and sTNFR-II were comparable for advanced endometriosis and controls, and between early and advanced endometriosis. As a biomarker for all- stage endometriosis, sTNFR-I produces AUC of 0.62, sensitivity of 61%, and specificity of 47.3%, at a cutoff of 81.87 pg/ml. For early stage disease, sTNFR-I yields AUC of 0.68, sensitivity of 60.7%, specificity of 75%, at a cutoff of 351.22 pg/ml. Conclusion sTNFR-I is significantly higher in serum of endometriosis patients than controls. As an endometriosis biomarker, sTNFR-I achieves better performance for early stage disease.

AB - Introduction We examine serum levels sTNFR-I and sTNFR-II in endometriosis patients, and their role as biomarkers of endometriosis. Material and methods Women were diagnosed with endometriosis during laparoscopy to investigate pelvic pain and/or infertility (N = 62). Control group included women with pelvic pain and/or infertility, whose laparoscopy showed no abnormalities (N = 55). Serum concentrations of sTNFR-I and sTNFR-II were measured using Bioplex Protein Array system. Non-parametric statistics were used. Results Endometriosis patients had significantly higher levels of sTNFR-I than controls (257.46 pg/ml, IQR = 2.37-1048.92 versus 130.39 pg/ml, IQR = 0.99-361.1 respectively, P value = 0.01). For TNFR-II, difference between women with (232 pg/ml, IQR = 0.0-624.4), and women without (132.93 pg/ml, IQR = 0.0-312.81) endometriosis was not significant (P value = 0.05). Early stage endometriosis patients had significantly higher level of sTNFR-I (559.13, IQR = 1.82-1289.86) and sTNFR-II (248.8, IQR = 0-644.65) than control women (P value is 0.01 for TNFR-I and 0.04 for TNFR-II). Levels of sTNFR-I and sTNFR-II were comparable for advanced endometriosis and controls, and between early and advanced endometriosis. As a biomarker for all- stage endometriosis, sTNFR-I produces AUC of 0.62, sensitivity of 61%, and specificity of 47.3%, at a cutoff of 81.87 pg/ml. For early stage disease, sTNFR-I yields AUC of 0.68, sensitivity of 60.7%, specificity of 75%, at a cutoff of 351.22 pg/ml. Conclusion sTNFR-I is significantly higher in serum of endometriosis patients than controls. As an endometriosis biomarker, sTNFR-I achieves better performance for early stage disease.

KW - Endometriosis

KW - Non invasive diagnosis

KW - Serum

KW - Soluble TNF receptors

UR - http://www.scopus.com/inward/record.url?scp=84960105303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960105303&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2016.02.025

DO - 10.1016/j.ejogrb.2016.02.025

M3 - Article

C2 - 26963895

AN - SCOPUS:84960105303

VL - 200

SP - 1

EP - 5

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

ER -